Moberg Pharma: Question marks straightened out, but uncertainty about approval in the US remains
Research Note
2020-01-23
11:42
The expert evaluation of the MOB-015 North American Phase 3 study results, presented yesterday, provides a credible explanation of why the complete cure data (primary endpoint) was surprisingly weak, meanwhile, the data of mycological cure was impressively strong. A solution to the problem is also suggested, but that would require a new clinical trial.
KP
Klas Palin
Disclosures and disclaimers